Annette Stein

Suggest Changes
Learn More
PURPOSE Low-dose (LD) interferon (IFN) alfa (LDI) has demonstrated a consistent disease-free survival benefit for patients with clinically lymph node-negative melanoma in clinical trials. However,(More)
PURPOSE To evaluate the efficacy, safety, tolerability, and quality of life (QoL) in patients receiving intravenous, intermittent high-dose interferon alfa-2b (IFN-α-2b [iHDI]) compared with standard(More)
Background In most countries, approved botulinum toxin type A formulations require reconstitution before injection. Objectives To evaluate the efficacy and safety of a ready-to-use liquid(More)